Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience

@article{Specchia2007GemtuzumabOW,
  title={Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience},
  author={Giorgina Specchia and Domenico Pastore and Paola Carluccio and Giuseppe Spinosa and Margherita Giannoccaro and Rita Rizzi and Anna Mestice and Vincenzo Liso},
  journal={Annals of Hematology},
  year={2007},
  volume={86},
  pages={425-428}
}
We analyzed the safety and efficacy of gemtuzumab ozogamicin (GO) combined with cytarabine and mitoxantrone in the treatment of 21 patients with acute myeloid leukemia (11 refractory and 10 in second relapse). Patients’ median age was 52 years (range 36–68); all patients had previously been treated with anthracycline-containing regimens (daunorubicin and idarubicin). GO at a dosage of 3 mg/m2 was administered as a 2-h intravenous infusion on days 1 and 14, cytarabine at 100 mg/m2 on days 1–7… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

Cancer immunotherapy.

Cancer biotherapy & radiopharmaceuticals • 2011

References

Publications referenced by this paper.
Showing 1-10 of 19 references

Acute myeloid leukemia.

Hematology. American Society of Hematology. Education Program • 2004
View 2 Excerpts

Similar Papers

Loading similar papers…